<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    9207819
   </pmid>
   <datecreated>
    <year>
     1997
    </year>
    <month>
     07
    </month>
    <day>
     31
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1997
    </year>
    <month>
     07
    </month>
    <day>
     31
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     10
    </month>
    <day>
     26
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0029-7844
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       90
      </volume>
      <issue>
       1
      </issue>
      <pubdate>
       <year>
        1997
       </year>
       <month>
        Jul
       </month>
      </pubdate>
     </journalissue>
     <title>
      Obstetrics and gynecology
     </title>
     <isoabbreviation>
      Obstet Gynecol
     </isoabbreviation>
    </journal>
    <articletitle>
     Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy.
    </articletitle>
    <pagination>
     <medlinepgn>
      83-7
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To determine whether ranitidine (Zantac) taken once or twice daily is effective for relieving symptoms of gastroesophageal reflux among pregnant women who had failed conservative measures.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      Volunteers with heartburn despite antacids were sought among our obstetrics clinic population for this double-blind, placebo-controlled, triple crossover trial. After a baseline week, 20 patients were randomized to receive the three following weekly regimens: ranitidine 150 mg twice daily, placebo in the morning and ranitidine 150 mg in the evening, or placebo twice daily. Daily scores on symptom diaries, global assessments, and number of antacids taken were compared among the 18 patients completing the study.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      The twice-daily dosage of ranitidine was the only regimen found to reduce heartburn symptoms when compared with the baseline (P &lt; .001) or a placebo (P &lt; .01). Compared with ranitidine taken once daily, the twice-daily dosing prompted less need for antacid tablets compared with the placebo (P &lt; .05 versus P &gt; .05) and to the baseline (P &lt; .001 versus P &lt; .05). The average reduction of heartburn severity using twice-daily ranitidine was 55.6% when compared with baseline (95% confidence interval [CI] 34.8%, 76.5%) was 44.2% when compared with placebo (95% CI 15.4%, 72.9%).
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      This study indicates the efficacy of ranitidine 150 mg taken twice daily, rather than once daily, for relief of gastroesophageal reflux symptoms during pregnancy.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Obstetrics and Gynecology, University of Oklahoma College of Medicine, Oklahoma City, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Larson
      </lastname>
      <forename>
       J D
      </forename>
      <initials>
       JD
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Patatanian
      </lastname>
      <forename>
       E
      </forename>
      <initials>
       E
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Miner
      </lastname>
      <forename>
       P B
      </forename>
      <initials>
       PB
      </initials>
      <suffix>
       Jr
      </suffix>
     </author>
     <author validyn="Y">
      <lastname>
       Rayburn
      </lastname>
      <forename>
       W F
      </forename>
      <initials>
       WF
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Robinson
      </lastname>
      <forename>
       M G
      </forename>
      <initials>
       MG
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     Obstet Gynecol
    </medlineta>
    <nlmuniqueid>
     0401101
    </nlmuniqueid>
    <issnlinking>
     0029-7844
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Histamine H2 Antagonists
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      66357-35-5
     </registrynumber>
     <nameofsubstance>
      Ranitidine
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cross-Over Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Gastroesophageal Reflux
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Heartburn
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Histamine H2 Antagonists
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pregnancy
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pregnancy Complications
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Ranitidine
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1997
     </year>
     <month>
      7
     </month>
     <day>
      1
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2001
     </year>
     <month>
      3
     </month>
     <day>
      28
     </day>
     <hour>
      10
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1997
     </year>
     <month>
      7
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     9207819
    </articleid>
    <articleid idtype="pii">
     S0029-7844(97)00126-9
    </articleid>
    <articleid idtype="doi">
     10.1016/S0029-7844(97)00126-9
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

